Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H30N2O2 |
| Molecular Weight | 438.5607 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CN(C[C@@]1([H])C(CCC2=O)(C3=CC=CC=C3)C4=CC=CC=C4)C(=N)CC5=CC=CC=C5OC
InChI
InChIKey=VWBOQFANCXZMAU-LOSJGSFVSA-N
InChI=1S/C29H30N2O2/c1-33-27-15-9-8-10-21(27)18-28(30)31-19-24-25(20-31)29(17-16-26(24)32,22-11-4-2-5-12-22)23-13-6-3-7-14-23/h2-15,24-25,30H,16-20H2,1H3/t24-,25+/m0/s1
| Molecular Formula | C29H30N2O2 |
| Molecular Weight | 438.5607 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
RP-67580 selectively inhibits the binding of substance-P to Neurokinin Receptor-1 and does not show meaningful antagonistic activity against NK2 and NK3. Preclinical trials had been conducted and discontinued in France for the potential treatment of inflammation and pain. RP-67580 has not been used in human trials.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P25103 Gene ID: 6869.0 Gene Symbol: TACR1 Target Organism: Homo sapiens (Human) |
30.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Molecular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580. | 1992 Dec 25 |
|
| RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. | 1993 Jun 25 |
|
| Characterization of the capsaicin-sensitive component of cyclophosphamide-induced inflammation in the rat urinary bladder. | 1994 Apr |
|
| Involvement of spinal tachykinin NK1 and NK2 receptors in detrusor hyperreflexia during chemical cystitis in anaesthetized rats. | 1994 Jul 1 |
|
| Role of intrathecal tachykinins for micturition in unanaesthetized rats with and without bladder outlet obstruction. | 1994 Sep |
|
| Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins? | 1995 Jun |
|
| Substance P and capsaicin-induced mechanical hyperalgesia in the rat knee joint; the involvement of bradykinin B1 and B2 receptors. | 1996 Aug |
|
| Influence of several peptidase inhibitors on the pro-inflammatory effects of substance P, capsaicin and collagenase. | 1996 Nov |
|
| Effect of tachykinin receptor antagonists in experimental neuropathic pain. | 1998 Nov 20 |
|
| Role of supraspinal tachykinins for volume- and L-dopa-induced bladder activity in normal conscious rats. | 2000 |
|
| Activation of central neurokinin-1 receptors induces reinstatement of cocaine-seeking behavior. | 2005 Dec 16 |
|
| Involvement of substance P and neurogenic inflammation in arsenic-induced early vascular dysfunction. | 2007 Jan |
|
| Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. | 2007 Nov 8 |
|
| Interdependent regulation of afferent renal nerve activity and renal function: role of transient receptor potential vanilloid type 1, neurokinin 1, and calcitonin gene-related peptide receptors. | 2008 Jun |
|
| NK-1 receptors in the rostral ventromedial medulla contribute to hyperalgesia produced by intraplantar injection of capsaicin. | 2008 Sep 30 |
|
| Activation of TRPV1 by capsaicin induces functional kinin B(1) receptor in rat spinal cord microglia. | 2012 Jan 20 |
|
| Microvascular dysfunction with increased vascular leakage response in mice systemically exposed to arsenic. | 2014 Sep |
Sample Use Guides
RP-67580 was studied in rats as a mediator of substance P-induced (SP) knee pain. Rats received an inferior alveolar injection of SP followed by treatment with 20 - 200 nmol RP-67580 delivered as an inferior alveolar injection. In mouse model of trypanosomiasis RP-67580 was administered intraperitoneally at dose 2 mg/kg twice daily for 10 days.
Route of Administration:
Other
Human A549 adenocarcinoma cells were cultured in DMEM containing 10% FBS, 100 units/ml penicillin, 100 microgram/ml streptomycin, and 2 mM glutamine. A549 cells were transfected with cDNA for Tacr1, a firefly NF-kB-luciferase reporter gene, and the Renilla luciferase plasmid pRL-TK. Cells were treated with 10^-7 M substance P (SP) 24 h after transfection, and cells were collected for luciferase assay 4 h following treatment. The NK1 inhibitor RP-67580 was added 40 min prior to SP pro-inflammatory treatment, in a range of concentrations from 10^-7 to 10^-4 M. RP-67580 exhibited a dose-dependent inhibition of NF-kB-luciferase activation by SP.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:11:50 GMT 2023
by
admin
on
Fri Dec 15 18:11:50 GMT 2023
|
| Record UNII |
49U9M41BGY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID30929179
Created by
admin on Fri Dec 15 18:11:50 GMT 2023 , Edited by admin on Fri Dec 15 18:11:50 GMT 2023
|
PRIMARY | |||
|
107686
Created by
admin on Fri Dec 15 18:11:50 GMT 2023 , Edited by admin on Fri Dec 15 18:11:50 GMT 2023
|
PRIMARY | |||
|
135911-02-3
Created by
admin on Fri Dec 15 18:11:50 GMT 2023 , Edited by admin on Fri Dec 15 18:11:50 GMT 2023
|
PRIMARY | |||
|
49U9M41BGY
Created by
admin on Fri Dec 15 18:11:50 GMT 2023 , Edited by admin on Fri Dec 15 18:11:50 GMT 2023
|
PRIMARY |